Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 590

Results For "GE"

8420 News Found

Ashland to expand bioresorbable polymers capacity in Ireland
News | September 02, 2022

Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024


Centre grants approval of three Bulk Drug Parks
Policy | September 02, 2022

Centre grants approval of three Bulk Drug Parks

The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly


Infosys completes acquisition of BASE life science
Digitisation | September 02, 2022

Infosys completes acquisition of BASE life science

The acquisition reaffirms Infosys’ commitment to help global life sciences companies


Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility
News | September 02, 2022

Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility

The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers


Bayer showcases cancer study data at ESMO Congress 2022
News | September 01, 2022

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors


Zydus receives final approval from USFDA for two tablets
Drug Approval | September 01, 2022

Zydus receives final approval from USFDA for two tablets

The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04


US FDA issues 17 observations for Biocon Biologics sites
News | September 01, 2022

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools


Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | September 01, 2022

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise